88 related articles for article (PubMed ID: 26268909)
21. Missing Data: How to Best Account for What Is Not Known.
Newgard CD; Lewis RJ
JAMA; 2015 Sep; 314(9):940-1. PubMed ID: 26325562
[No Abstract] [Full Text] [Related]
22. [Captopril reduction of albuminuria in type-II diabetics with diabetic nephropathy].
Melchor-Ortiz JL; Wacher-Rodarte N; Halabe-Cherem J; Lifshitz-Guinzberg A
Gac Med Mex; 1991; 127(3):261-6. PubMed ID: 1800220
[TBL] [Abstract][Full Text] [Related]
23. Arginine reduces kidney collagen accumulation, cross-linking, lipid peroxidation, glycoxidation, kidney weight and albuminuria in the diabetic kk mouse.
Lubec B; Aufricht C; Amann G; Kitzmüller E; Höger H
Nephron; 1997; 75(2):213-8. PubMed ID: 9041544
[TBL] [Abstract][Full Text] [Related]
24. Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice.
Nasrallah R; Robertson SJ; Hébert RL
Am J Nephrol; 2009; 30(4):346-53. PubMed ID: 19609076
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Shen X; Zhang Z; Zhang X; Zhao J; Zhou X; Xu Q; Shang H; Dong J; Liao L
Lipids Health Dis; 2016 Oct; 15(1):179. PubMed ID: 27733168
[TBL] [Abstract][Full Text] [Related]
26. [Renal disease by type 2 diabetes].
Persson F; Rossing P
Ugeskr Laeger; 2012 Sep; 174(37):2150-4. PubMed ID: 22971295
[TBL] [Abstract][Full Text] [Related]
27. [Type 2 diabetes mellitus and chronic kidney disease].
Ponťuch P
Vnitr Lek; 2017; 63(3):188-192. PubMed ID: 28379021
[TBL] [Abstract][Full Text] [Related]
28. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
Mazerska M; Myśliwiec M
Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
[TBL] [Abstract][Full Text] [Related]
29. [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
MMW Fortschr Med; 2003 Apr; 145(17):55. PubMed ID: 12808810
[No Abstract] [Full Text] [Related]
30. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
31. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
[TBL] [Abstract][Full Text] [Related]
32. Awareness of albuminuria in an Italian population-based cohort of patients treated with hypoglycemic drugs.
Degli Esposti L; Saragoni S; Buda S; Sturani A; Quintaliani G; Bartolucci S; Di Turi R; Lilli P; Didoni G; Degli Esposti E
J Nephrol; 2012; 25(3):325-31. PubMed ID: 21748718
[TBL] [Abstract][Full Text] [Related]
33. Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in patients with non-insulin dependent diabetes mellitus.
Nishikawa T; Omura M; Iizuka T; Saito I; Yoshida S
Arzneimittelforschung; 1996 Sep; 46(9):875-8. PubMed ID: 8876935
[TBL] [Abstract][Full Text] [Related]
34. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
Chantrel F; Bouiller M; Kolb I; Hannedouche T
Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis, implication, prevention and treatment of microalbuminuria].
Bothe D
Dtsch Med Wochenschr; 2012 Nov; 137(46):2390; author reply 2390-1. PubMed ID: 23132160
[No Abstract] [Full Text] [Related]
36. Treating diabetic nephropathy--are there only economic issues?
Mitch WE
N Engl J Med; 2004 Nov; 351(19):1934-6. PubMed ID: 15516698
[No Abstract] [Full Text] [Related]
37. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes.
Doggen K; Nobels F; Scheen AJ; Van Crombrugge P; Van Casteren V; Mathieu C
J Diabetes Complications; 2013; 27(4):370-5. PubMed ID: 23537603
[TBL] [Abstract][Full Text] [Related]
39. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
Feldt-Rasmussen BF
Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
[No Abstract] [Full Text] [Related]
40. Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes.
El Boustany R; Taveau C; Chollet C; Velho G; Bankir L; Alhenc-Gelas F; Roussel R; Bouby N
J Diabetes Complications; 2017 Jun; 31(6):929-932. PubMed ID: 28412033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
